

## Clinical Guideline

# Adrenarche

Management of children presenting with signs of early onset pubic hair/  
body odour/ acne

Includes guidance for the distinction between adrenarche, precocious puberty and  
other abnormalities of secondary sexual development

Dr Sarah Kiff, Consultant Paediatric Endocrinologist, NHS Lothian

Dr Louise Bath, Consultant in Paediatric Endocrinology and Diabetes, NHS Lothian

Approved by the SPEG Guidelines Group

Date of Issue: March 2015

Review Date: 05/02/2022

To be reviewed: 05/02/2025

### NOTE

This guideline is not intended to be construed or to serve as a standard of care. Standards of care are determined on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge and technology advance and patterns of care evolve. Adherence to guideline recommendations will not ensure a successful outcome in every case, nor should they be construed as including all proper methods of care or excluding other acceptable methods of care aimed at the same results. The ultimate judgement must be made by the appropriate healthcare professional(s) responsible for clinical decisions regarding a particular clinical procedure or treatment plan. This judgement should only be arrived at following discussion of the options with the patient, covering the diagnostic and treatment choices available. It is advised, however, that significant departures from the national guideline or any local guidelines derived from it should be fully documented in the patient's case notes at the time the relevant decision is taken.

## Contents

Purpose of this document.....	3
Who should use this document .....	3
Patients to whom this document applies .....	3
Definition of adrenarche .....	3
Clinical features.....	3
Biochemical findings.....	3
Clinical significance .....	3
Primary or secondary care .....	4
Interpretation of clinical findings and investigation results.....	5
References.....	6

## Purpose of this document

- To guide evaluation of a child presenting with features suggestive of adrenarche.
- To guide the distinction between adrenarche, precocious puberty and other abnormalities of secondary sexual development.

## Who should use this document

General practitioners, paediatricians and paediatric endocrinologists.

## Patients to whom this document applies

*Children presenting with pubic hair growth, axillary hair, body odour and acne before the expected age of puberty.*

## Definition of adrenarche

Adrenarche is the gradual increase in adrenal androgen secretion after approximately the age of 6 years in girls and 7 years in boys. It occurs independently from the gonadotrophin-dependent activation of the gonads in central puberty.

## Clinical features

Adrenarche results in the development of pubic hair, axillary hair, body odour and acne. (It does not result in the enlargement of the breasts, penis or testes).

## Biochemical findings


At the time of adrenarche, there is maturation of the adrenal glands, with increased production of dehydroepiandrosterone sulphate (DHEAS) relative to cortisol. The serum concentration of DHEAS can be used as a marker for the presence of adrenarche, with serum testosterone and androstenedione levels being near the upper limit of the normal range. However, the diagnosis can be made on clinical features without further investigations (see next page)

## Clinical significance

**Adrenarche is a normal variant of pubertal development.** It is important to distinguish this from precocious puberty and virilising conditions such as androgen secreting tumours and Congenital Adrenal hyperplasia. Adrenarche itself does not require treatment\*.

\*There has been previous concern that adrenarche may be associated with the development of insulin resistance, polycystic ovarian syndrome and metabolic syndrome, but this does not alter management or follow-up.

## Primary or secondary care



## Interpretation of clinical findings and investigation results

	<b>Breast/testicular development</b>	<b>Clitoral/penile growth</b>	<b>Linear growth acceleration</b>	<b>Bone Age</b>	<b>Androgens</b>	<b>Gonadotrophins</b>
<b>Premature adrenarche</b>	Absent	Absent	Absent, or slight initial acceleration	Up to 2 years advanced on chronological age Correlated with height age	Early pubertal, DHEAS may be moderately elevated	Prepubertal
<b>Precocious puberty</b>	Stage 2+ breast development ≥ 4ml testicular volume	Absent or early	Progressively accelerated	Progressively accelerated	May be normal or elevated for age Oestradiol may be elevated	Early pubertal (If suppressed consider oestrogen secreting tumour)
<b>Congenital adrenal hyperplasia</b>	Absent	Enlargement	Moderately to markedly accelerated	Moderately or markedly advanced for age and pubertal stage	Moderately to markedly elevated	Prepubertal
<b>Virilising tumours</b>	Absent	Marked and progressive enlargement	Markedly accelerated	Markedly and progressively advanced	Markedly elevated	Prepubertal or suppressed
<b>Iatrogenic</b>	Absent	Marked and progressive enlargement	Markedly accelerated	Markedly and progressively advanced	Markedly elevated testosterone	Prepubertal or suppressed

## References

1. Williams RM, Ward CE, Hughes IA. Premature adrenarche. *Arch Dis Child* 2011; **97**: 250-254.
2. Bourguignon JP, Rosenfield RL. Precocious pubarche. *Practical Algorithms in Paediatric Endocrinology* 2007.
3. Ibanez L, Valls C, Marcos MV et al, Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. *J Clin Endocrinol Metab* 2004; **89**: 4331-7.
4. Ibanez L, Diaz R, Lopez-Bermejo A et al. Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism. *Rev Endocr Metab Disord* 2009; 10: 63-76.
5. Idkowiak J, Lavery GG, Dhir V et al. Premature adrenarche: novel lessons from early androgen excess. *Eur J Endocrinol* 2011; **165**:189-207.
6. Ghizzoni L, Milani S. The natural history of premature adrenarche. *J Paediatr Endocrinol Metabol.* 2000; **13** Suppl 5:1247-51.